Provectus CEO receives 22,609 preferred shares

The preferred shares are convertible into 226,090 common shares and will automatically convert on December 31, 2028, unless converted earlier.

Rhea-AI Filing Summary

Provectus Biopharmaceuticals, Inc. CEO Edward Pershing's outstanding principal and interest on an 8% unsecured convertible promissory note automatically converted on October 10, 2026, into 22,609 Series D-1 Convertible Preferred Stock shares at $2.862 per share. Each preferred share is convertible into 10 common shares. Pershing's reported direct holdings following the transaction were 2,998,534 preferred shares.

Insider Trade Summary

22,609 shares exercised/converted

Exercise 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note F3, F4	--	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock F1, F2	22,609	$0.00	$0.00

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 contracts (Direct); Series D-1 Convertible Preferred Stock — 2,998,534 contracts (Direct)

Footnotes (4)

1. F1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").
2. F2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.
3. F3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.
4. F4. On October 10, 2026, the 2025 Note converted into 22,609 shares of Series D-1 Preferred Stock.

Key Figures

Note conversion: 22,609 Series D-1 Convertible Preferred Stock shares Conversion price: $2.862 per share Preferred-to-common conversion ratio: 10 common shares per preferred share +3 more

6 metrics

Note conversion 22,609 Series D-1 Convertible Preferred Stock shares Automatically converted on October 10, 2026

Conversion price $2.862 per share Price for conversion of the 2025 Note into Series D-1 Preferred Stock

Preferred-to-common conversion ratio 10 common shares per preferred share Series D-1 Convertible Preferred Stock

Underlying common shares 226,090 common shares Underlying the 22,609 Series D-1 preferred shares

Direct preferred holdings after transaction 2,998,534 shares Reported following the October 10, 2026 transaction

Automatic conversion date December 31, 2028 Series D-1 preferred stock converts into common stock unless earlier converted

Key Terms

8% unsecured convertible promissory note, Series D-1 Convertible Preferred Stock, Certificate of Designation

3 terms

8% unsecured convertible promissory note financial

"the 8% unsecured convertible promissory note (the "2025 Note")"

Series D-1 Convertible Preferred Stock financial

"shares of Series D-1 Preferred Stock at a price per share"

Certificate of Designation regulatory

"terms of the Certificate of Designation"

A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many preferred shares did PVCT CEO Edward Pershing receive?

The 2025 Note automatically converted into 22,609 shares of Series D-1 Preferred Stock on October 10, 2026, at a conversion price of $2.862 per share.

When will PVCT's Series D-1 preferred shares automatically convert into common stock?

The Series D-1 Convertible Preferred Stock will automatically convert into common stock on December 31, 2028, unless earlier converted in accordance with its Certificate of Designation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/13/2026 - 06:22 AM EDT Accepted by SEC EDGAR 10/13/2026 - 06:22 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	10/10/2026		M			$60,000	10/10/2025	10/10/2026	Series D-1 Convertible Preferred Stock(3)(4)	22,609	$0	$645,000	D
Series D-1 Convertible Preferred Stock	(1)	10/10/2026		M		22,609		10/10/2026	(2)	Common Stock	226,090	$0	2,998,534	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On October 10, 2026, the 2025 Note converted into 22,609 shares of Series D-1 Preferred Stock.

	/s/ Ed Pershing	10/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)